Biotech · Private company
Catabasis Pharmaceuticals
Track this companyFree. Adds Catabasis Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- EdasalonexentPhase 3 · Muscular Dystrophy, DuchenneClinicalTrials.gov · fetched Nov 12, 2026
- EdasalonexentPhase 3 · Duchenne Muscular DystrophyClinicalTrials.gov · fetched Nov 12, 2026
- AtorvastatinPhase 1 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- CAT-2054Phase 1 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- CAT-2054-CPhase 1 · HypercholesterolemiaClinicalTrials.gov · fetched Nov 12, 2026
- Deflazacort 36Mg TabPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Edasalonexent 2000 mg TIDPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- Midazolam 2 MG/MLPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Study of Edasalonexent With Midazolam and Deflazacort in Healthy SubjectsPHASE1 · COMPLETED · started Aug 8, 2020ClinicalTrials.gov NCT04543370 · fetched Nov 12, 2026
- An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular DystrophyPHASE3 · TERMINATED · started Mar 14, 2019ClinicalTrials.gov NCT03917719 · fetched Nov 12, 2026
- Phase III Study of Edasalonexent in Boys With Duchenne Muscular DystrophyPHASE3 · COMPLETED · started Oct 2, 2018ClinicalTrials.gov NCT03703882 · fetched Nov 12, 2026
- Phase 1/2 Study in Boys With Duchenne Muscular DystrophyPHASE1_PHASE2 · COMPLETED · started Apr 1, 2016ClinicalTrials.gov NCT02439216 · fetched Nov 12, 2026
- A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy SubjectsPHASE1 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02374047 · fetched Nov 12, 2026